3 in 1 HIV pill - new breakthrough

HIV treatment for one tablet per day has been approved for the first time in the United States, the American Food and Drug Association said.

Atripla tablet (Photo: BBC)

The pill called Atripla, made by Bristol-Myers-Squibb and Gilead Sciences, is a combination of the three most commonly used HIV medicines, including efavirenz, tenofovir and emtricitabine. The pill will also be allowed to be used in Europe next year.

Currently, people with HIV still have to use separate pills containing efavirenz, tenofovir and emtricitabine. The number of pills they have to drink every day is up to several dozen tablets, although it has been reduced in recent years. This not only makes it difficult for patients but also leads to drug resistance once those patients do not use the prescribed medication.

Therefore, experts say that the birth of Atripla will be a new breakthrough in the fight against HIV / AIDS. Mike Leavitt, at the US Department of Health and Children, said: "This important breakthrough will help us in the fight against HIV / AIDS. I hope the stakeholders will quickly bring this drug out. market so it can reach those who need it ".

However, using Atripla will be very expensive, more than 1,000 USD per month.

MT